Study backs PDE-4 inhibitor for psoriatic arthritis

Patients on the oral phosphodiesterase 4 inhibitor apremilast reported clinically meaningful improvements in symptoms that were sustained over a year, a Phase III trial has shown.

The 505-person study randomised psoriatic arthritis patients who had failed prior treatment to either 20mg of apremilast twice daily, 30mg of apremilast twice daily or placebo.

After 16 weeks, 28% of patients who received the